- Home
- VTAK vs ADTX Comparison
VTAK vs ADTX Comparison
Compare VTAK & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTAK
- ADTX
- Stock Information
- Founded
- VTAK 2002
- ADTX 2017
- Country
- VTAK United States
- ADTX United States
- Employees
- VTAK N/A
- ADTX N/A
- Industry
- VTAK Medical/Dental Instruments
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- VTAK Health Care
- ADTX Health Care
- Exchange
- VTAK Nasdaq
- ADTX Nasdaq
- Market Cap
- VTAK 3.1M
- ADTX 3.1M
- IPO Year
- VTAK 2018
- ADTX 2020
- Fundamental
- Price
- VTAK $0.24
- ADTX $1.21
- Analyst Decision
- VTAK
- ADTX
- Analyst Count
- VTAK 0
- ADTX 0
- Target Price
- VTAK N/A
- ADTX N/A
- AVG Volume (30 Days)
- VTAK 41.3M
- ADTX 1.9M
- Earning Date
- VTAK 08-13-2025
- ADTX 08-18-2025
- Dividend Yield
- VTAK N/A
- ADTX N/A
- EPS Growth
- VTAK N/A
- ADTX N/A
- EPS
- VTAK N/A
- ADTX N/A
- Revenue
- VTAK $481,000.00
- ADTX $55,323.00
- Revenue This Year
- VTAK $822.86
- ADTX $15,768.94
- Revenue Next Year
- VTAK $168.42
- ADTX N/A
- P/E Ratio
- VTAK N/A
- ADTX N/A
- Revenue Growth
- VTAK 9.57
- ADTX N/A
- 52 Week Low
- VTAK $0.16
- ADTX $1.05
- 52 Week High
- VTAK $4.76
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- VTAK 45.34
- ADTX 38.39
- Support Level
- VTAK $0.22
- ADTX $1.05
- Resistance Level
- VTAK $0.25
- ADTX $1.35
- Average True Range (ATR)
- VTAK 0.02
- ADTX 0.20
- MACD
- VTAK -0.01
- ADTX 0.02
- Stochastic Oscillator
- VTAK 11.79
- ADTX 14.04
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.